Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Boehringer Ingelheim Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (87)
Cancellation by sponsor (44)
Prescription medicine registration (10)
Australian Public Assessment Report (AusPAR) (7)
Designation or determination (2)
Prescription medicine decision summary (1)
Prescription medicine evaluation (1)

Date

2024 (6)
2023 (9)
2022 (3)
2021 (6)
2020 (14)
2019 (2)
2018 (15)
2017 (4)
2016 (16)
2015 (13)
2014 (4)
2013 (14)
2012 (3)
2011 (8)
2010 (5)
2008 (4)
2007 (2)
2003 (1)
2002 (3)
2001 (4)
2000 (3)
1999 (7)
1998 (1)
1996 (1)
1993 (1)
1992 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

152 result(s) found, displaying 51 to 60

OFEV nintedanib (as esilate) 150 mg soft capsule blister pack (226068)

1 September 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for OFEV nintedanib (as esilate) 150 mg soft capsule blister pack.
OFEV nintedanib (as esilate) 100 mg soft capsule blister pack (226065)

1 September 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for OFEV nintedanib (as esilate) 100 mg soft capsule blister pack.
FAVINT tiotropium 18 micrograms powder for inhalation (in capsule) blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
FAVINT RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
VIRAMUNE XR nevirapine 100 mg extended-release tablet bottle Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 5 mg / 850 mg empagliflozin/metformin hydrochloride 5mg/850mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 5 mg / 1000 mg empagliflozin/metformin hydrochloride 5mg/1000mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 12.5 mg / 500 mg empagliflozin/metformin hydrochloride 12.5mg/500mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCEMET 12.5 mg / 850 mg empagliflozin/metformin hydrochloride 12.5mg/850mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

3 May 2018

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd

Pages

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.